Skip to main content
TipRanks
Go Ultimate75% OFF

Lexicon Pharmaceuticals (LXRX) AI Stock Analysis

1,836 Followers
LXRX

Lexicon Pharmaceuticals

(NASDAQ:LXRX)

Select Model
Rating:49Neutral
Price Target:$1.50â–¼(-14.29% Downside)
Action:reiterated
Date:11/06/26

LXRX scores below average primarily due to weak financial performance (ongoing large losses and cash burn despite a debt-free balance sheet) and only modest technical strength (below key longer-term moving averages with negative MACD). The earnings call improves the outlook with clear near-term clinical/regulatory catalysts and maintained expense guidance, but valuation remains constrained by lack of profitability and no dividend support.

Positive Factors
Debt-free balance sheetA debt-free balance sheet gives Lexicon greater financial flexibility while its pipeline advances through clinical and regulatory milestones. The absence of reported debt reduces refinancing and interest burdens, allowing more resources to remain available for research, development, and pre-commercial preparation.
Negative Factors
Persistent operating lossesDeep operating and net losses show that Lexicon has not yet converted its development portfolio into a self-sustaining earnings model. Even with losses narrowing versus 2024, continued negative profitability can constrain reinvestment capacity and leave future progress dependent on financing, milestones, or commercialization.

Lexicon Pharmaceuticals (LXRX) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%LXRX+32.58%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$779.16M
Dividend Yield
―
Average Volume (3M)
2.60M
Price to Earnings (P/E)
-12.0
Beta (1Y)
1.45
Revenue Growth
-45.62%
EPS Growth
21.16%
Country
US
Employees
81
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Lexicon Pharmaceuticals Business Overview & Revenue Model

Company Description

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug...

How the Company Makes Money

Lexicon Pharmaceuticals makes money primarily through a combination of (1) collaboration and licensing arrangements and (2) any product-related revenue from commercialized drugs, if applicable, along with (3) other operating income sources typical fo...

Lexicon Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:18.24%|Next Earnings Date:Mar 11, 2027
Earnings Call SentimentPositive

The call was predominantly positive, with management highlighting completed SONATA-HCM enrollment, encouraging STENO1 safety data, the planned ZYNQUISTA NDA resubmission, regulatory progress through Viatris, a $10 million LX9851 milestone, promising pilavapadin weight-loss data, and a higher cash balance. The principal negatives were lower year-over-year revenue, a larger net loss, higher SG&A expenses, and delays and administrative complexity surrounding the ZYNQUISTA resubmission. Multiple significant clinical and regulatory catalysts expected in the first quarter of 2027 supported an overall favorable tone.

Positive Updates

SONATA-HCM Enrollment Completed
Lexicon completed enrollment in the phase III SONATA-HCM study, which included 542 patients: 440 with non-obstructive HCM and 102 with obstructive HCM. The study population had a mean baseline KCCQ score of 59, reflecting a highly symptomatic population, and top-line results are expected in the first quarter of 2027.

Negative Updates

Revenue Declined Year Over Year
Third-quarter 2026 revenue was $11.3 million, compared with $14.2 million in the corresponding period of 2025, a decrease of approximately 20%. The prior-year quarter included $13.2 million of Novo Nordisk licensing revenue, compared with $10 million of milestone revenue in the third quarter of 2026.

Company Guidance

Lexicon maintained its 2026 operating expense guidance of between $100 million and $110 million, with R&D expected to be between $63 million and $68 million and SG&A expected to be between $37 million and $42 million; the company expects SONATA-HCM top-line results in the first quarter of 2027, expects to complete the ZYNQUISTA NDA resubmission in the first quarter of 2027, expects SOTA-CROSS completion in 2027, and expects additional milestone payments as LX9851 advances.

Lexicon Pharmaceuticals Financial Statement Overview

Summary

Financial fundamentals are weak overall: revenue declined (~7% TTM) and the company remains deeply unprofitable (EBIT -$56.8M; net loss -$62.4M; net margin ~-162%) with ongoing cash burn (TTM FCF -$49.2M). The key offset is a healthier balance sheet with $0 debt and meaningful equity, plus improving losses versus 2024, but profitability and self-funding are still not in place.

Income Statement

24Negative

Balance Sheet

62Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue38.54M49.80M31.08M1.20M139.00K298.00K
Gross Profit37.99M49.53M30.46M-57.77M-52.38M-54.75M
EBITDA-56.19M-41.38M-184.29M-169.76M-100.03M-86.66M
Net Income-62.35M-50.34M-200.40M-177.12M-101.94M-87.76M
Balance Sheet
Total Assets242.02M184.99M298.42M229.43M194.30M136.91M
Cash, Cash Equivalents and Short-Term Investments183.20M96.23M237.96M170.03M138.36M86.74M
Total Debt59.54M62.24M108.40M106.06M55.29M2.28M
Total Liabilities78.18M77.45M152.47M136.32M77.17M23.31M
Stockholders Equity163.84M107.54M145.95M93.11M117.12M113.59M
Cash Flow
Free Cash Flow-63.96M-67.85M-179.81M-162.37M-90.18M-88.24M
Operating Cash Flow-63.96M-67.85M-178.78M-161.90M-88.85M-87.02M
Investing Cash Flow-140.98M113.02M-15.38M-49.94M-71.08M2.11M
Financing Cash Flow174.13M-48.50M238.35M187.96M142.21M22.71M

Lexicon Pharmaceuticals Technical Analysis

Technical Analysis SentimentNeutral
Last Price1.75

Price Trends

50DMA1.76Negative
100DMA2.04Negative
200DMA1.90Negative

Market Momentum

MACD0.02Negative
RSI54.71Neutral
STOCH65.65Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXRX, the sentiment is Neutral. The current price of 1.75 is above the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.76, and below the 200-day MA of 1.90, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.71 is Neutral, neither overbought nor oversold. The STOCH value of 65.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LXRX.

Lexicon Pharmaceuticals Risk Analysis

Lexicon Pharmaceuticals disclosed 38 risk factors in its most recent earnings report. Lexicon Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.If we are unable to meet Nasdaq continued listing requirements, including minimum trading price, Nasdaq may take action to delist our common stock.Q4, 2024
2.We depend heavily on our ability to successfully complete the ongoing research and development of our drug programs. If we fail to successfully complete and gain positive results from such research and development efforts, our business will suffer and our stock price will likely decline.Q4, 2024
3.Changes in government trade policies could disrupt our supply chain or increase the costs of our clinical and commercial supply, negatively impacting our ability to conduct our clinical and commercial operations, price our commercial product competitively and conduct clinical development in a cost effective manner.Q4, 2024

Lexicon Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

LXRX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
RIGLRIGL79Outperform$823.43M2.5873.94%―2.18%165.65%
INVAINVA61Neutral$1.31B7.3115.84%―12.38%34.41%
MNKDMNKD55Neutral$1.27B-16.75139.41%―31.74%-344.30%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ARDXARDX49Neutral$771.71M-13.56-35.30%―17.57%4.82%
LXRXLXRX49Neutral$779.16M-12.01-38.44%―-45.62%21.16%
VNDAVNDA39Underperform$230.39M-0.82-106.94%―8.11%-222.50%

* Healthcare Sector Average

Performance Comparison

-50%0%50%LXRXMNKDRIGLINVAVNDAARDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
LXRX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
LXRXLexicon Pharmaceuticals1.750.3020.69%
MNKDMannKind Corporation3.96-1.04-20.90%
RIGLRigel Pharmaceuticals43.732.054.92%
INVAInnoviva18.49-2.78-13.07%
VNDAVanda Pharmaceuticals3.81-1.33-25.88%
ARDXArdelyx Inc3.07-2.50-44.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026